Literature DB >> 20237037

Prognostic implication of dual-phase PET in adenocarcinoma of the lung.

Mohamed Houseni1, Wichana Chamroonrat, Jiyuan Zhuang, Rohit Gopal, Abass Alavi, Hongming Zhuang.   

Abstract

UNLABELLED: The purpose of this study was to determine whether dual-phase (18)F-FDG PET could be a prognostic factor for adenocarcinoma of the lung.
METHODS: One hundred patients with histologically proven adenocarcinoma of the lung were included in this retrospective analysis. All patients underwent dual-phase pretherapy (18)F-FDG PET for which, after the intravenous administration of (18)F-FDG, both early (approximately 60 min) and delayed (approximately 90 min) PET were acquired. The percentage change in the maximal standardized uptake values (SUVmax) of the cancer between the early and the delayed images was calculated. Overall survival of the SUVmax change over time together with the known prognostic factors were calculated by the Kaplan-Meier method and evaluated with the log-rank test. The prognostic significance was assessed by univariate and multivariate analyses.
RESULTS: Statistical analysis showed that SUVmax change over time between the early and the delayed PET was a strong independent predictor of outcome for lung adenocarcinoma. A cutoff of 25% change for SUVmax over time showed the best discriminative value. Patients with more than 25% increase in SUVmax had a median survival of 15 mo, compared with 39 mo for those with less than 25% increase in SUVmax.
CONCLUSION: Dual-phase (18)F-FDG PET reflects the dynamics of glucose metabolism. Our findings suggest that the percentage SUVmax change over time is a strong prognostic factor in patients with lung adenocarcinoma and can be complementary to the other well-known factors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20237037     DOI: 10.2967/jnumed.109.068643

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

1.  Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer.

Authors:  Hao Zhang; Kristen Wroblewski; Daniel Appelbaum; Yonglin Pu
Journal:  Int J Comput Assist Radiol Surg       Date:  2012-05-30       Impact factor: 2.924

2.  Peripheral Tuberculous Lymphadenitis Masquerading as Metastatic Gastric Carcinoma on F-18 FDG Dual Time Point PET/CT.

Authors:  Su Kon Kim; Jeong Eun Shin; Jai Hyuen Lee
Journal:  Nucl Med Mol Imaging       Date:  2012-09-08

3.  Prediction of response to neoadjuvant chemotherapy in osteosarcoma using dual-phase (18)F-FDG PET/CT.

Authors:  Byung Hyun Byun; Sung Hoon Kim; Sang Moo Lim; Ilhan Lim; Chang-Bae Kong; Won Seok Song; Wan Hyeong Cho; Dae-Geun Jeon; Soo-Yong Lee; Jae-Soo Koh; Soo Kyo Chung
Journal:  Eur Radiol       Date:  2015-02-14       Impact factor: 5.315

4.  Relationship Between Dual-Time Point FDG PET and Immunohistochemical Parameters in Preoperative Colorectal Cancer: Preliminary Study.

Authors:  Jai Hyuen Lee; Won Ae Lee; Seok Gun Park; Dong Kook Park; Hwan Namgung
Journal:  Nucl Med Mol Imaging       Date:  2012-01-03

5.  The increment in standardized uptake value determined using dual-phase 18F-FDG PET is a promising prognostic factor in non-small-cell lung cancer.

Authors:  Helen H W Chen; Bi-Fang Lee; Wu-Chou Su; Yu-Hsuan Lai; Hung-Yu Chen; How-Ran Guo; Wei-Jen Yao; Nan-Tsing Chiu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-06-07       Impact factor: 9.236

6.  Prognostic Value of Dual-Time-Point [18F]FDG PET/CT for Predicting Distant Metastasis after Treatment in Patients with Non-Small Cell Lung Cancer.

Authors:  Sang Mi Lee; Jeong Won Lee; Ji-Hyun Lee; In Young Jo; Su Jin Jang
Journal:  J Pers Med       Date:  2022-04-07

7.  Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.

Authors:  Mitchell Machtay; Fenghai Duan; Barry A Siegel; Bradley S Snyder; Jeremy J Gorelick; Janet S Reddin; Reginald Munden; Douglas W Johnson; Larry H Wilf; Albert DeNittis; Nancy Sherwin; Kwan Ho Cho; Seok-Ki Kim; Gregory Videtic; Donald R Neumann; Ritsuko Komaki; Homer Macapinlac; Jeffrey D Bradley; Abass Alavi
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

Review 8.  PET in the management of locally advanced and metastatic NSCLC.

Authors:  Willem Grootjans; Lioe-Fee de Geus-Oei; Esther G C Troost; Eric P Visser; Wim J G Oyen; Johan Bussink
Journal:  Nat Rev Clin Oncol       Date:  2015-04-28       Impact factor: 66.675

9.  The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase (18)F-FDG PET/CT.

Authors:  Hansol Moon; Woo Chul Noh; Hyun-Ah Kim; Eun-Kyu Kim; Ko Woon Park; Seung Sook Lee; Joon Ho Choi; Kyung Woo Han; Byung Hyun Byun; Ilhan Lim; Byung Il Kim; Chang Woon Choi; Sang Moo Lim
Journal:  Nucl Med Mol Imaging       Date:  2016-04-11

10.  Prognostic value of the standardized uptake value maximum change calculated by dual-time-point (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with advanced non-small-cell lung cancer.

Authors:  Feng Jin; Hui Zhu; Zheng Fu; Li Kong; Jinming Yu
Journal:  Onco Targets Ther       Date:  2016-05-19       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.